Real-World Experience of Imipenem–Relebactam Treatment as Salvage Therapy in Difficult-to-Treat Pseudomonas aeruginosa Infections (IMRECOR Study)
Imipenem/cilastatin/relebactam may represent a treatment option for patients with DTR-P. aeruginosa infections, which should be validated in prospective clinical trials.
Authors
- Ángela Cano (ORCID: https://orcid.org/0000-0002-7801-9778)
- Luis Martı́nez-Martı́nez (ORCID: https://orcid.org/0000-0002-6091-4045)
- Irene Gracia-Ahufinger (ORCID: https://orcid.org/0000-0001-7714-6620)
- Andrés Martin (ORCID: https://orcid.org/0000-0001-6425-5158)
- Fátima Galán‐Sánchez (ORCID: https://orcid.org/0000-0003-0101-6701)
- R. Segura Iglesias
- Isabel Leiva‐Gea (ORCID: https://orcid.org/0000-0002-2259-7253)
- Juan José Castón (ORCID: https://orcid.org/0000-0002-7477-2033)
- Natividad Benito (ORCID: https://orcid.org/0000-0001-6410-013X)
- Isabel Machuca (ORCID: https://orcid.org/0000-0003-3343-0085)
- Jaume Revuelto
- Julián Torre-Cisneros
- Rosa Girón (ORCID: https://orcid.org/0000-0001-7094-0848)
- Elisa Ruiz-Arabi (ORCID: https://orcid.org/0000-0002-5833-4834)
- José Antonio Martínez
- Arantxa Domínguez
- Reynaldo Mauricio Rodríguez Amaya
- Cristina Arjona
- Maravillas Carralon
Institutions
- Instituto de Salud Carlos III (ES)
- Hospital de Sant Pau (ES)
- Instituto Maimónides de Investigación Biomédica de Córdoba (ES)
- Hospital Universitario Quirónsalud Madrid (ES)
- Hospital General de Granollers (ES)
- Centro de Investigación Biomédica en Red (ES)
- Hospital Clínic de Barcelona (ES)
- Complejo Hospitalario de Jaén (ES)
- Hospital Universitario Reina Sofía (ES)
- Hospital Universitario de La Princesa (ES)
- Hospital Universitario Puerta del Mar (ES)
- Hospital Universitario Virgen del Rocío (ES)
- University of Córdoba (ES)
- Cordoba University (US)
Publication Details
- Journal
- Infectious Diseases and Therapy
- Published
- 2024-11-29
- DOI
- https://doi.org/10.1007/s40121-024-01077-z
- Citations
- 8
- Primary Topic
- Antibiotic Resistance in Bacteria
- Type
- article
- Field-Weighted Citation Impact
- 1.36